Degeneration Versus Autoimmunity in Multiple Sclerosis

Annals of Neurology

Volumn 66, Issue 6, 2009, Pages 711-713

  Tsutsui, Shigeki ^a   Stys, Peter K ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTIINFLAMMATORY AGENT; MYELIN; N METHYL DEXTRO ASPARTIC ACID;

AUTOIMMUNITY; BRAIN DAMAGE; CELLULAR IMMUNITY; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; EDITORIAL; EXCITOTOXICITY; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; HUMANS; MULTIPLE SCLEROSIS; NERVE DEGENERATION;

EID: 73549114845     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21845     Document Type: Editorial

References (29)

1. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291-301.
2. Prat A, Antel J. Pathogenesis of multiple sclerosis. Curr Opin Neurol 2005;18:225-230.
3. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 2002;25:491-505.
4. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002;53:285-302.
5. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247-269.
6. Bennett JL, Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol 2009;32:121-132.
7. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007;6:903-912.
8. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
9. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304.
10. Henderson APD, Barnett MH, Parratt JDE, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009;66:739-753.
11. Gay F. Activated microglia in primary MS lesions: defenders or aggressors? Int MS J 2007;14:78-83.
12. Stys PK. Axonal degeneration in multiple sclerosis: is it time for neuroprotective strategies? Ann Neurol 2004;55:601-603.
13. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8:280-291.
14. Alix JJP, Fern R. Glutamate receptor-mediated ischemic injury of premyelinated central axons. Ann Neurol 2009;66:682-693.
15. Follett PL, Deng W, Dai W, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci 2004;24:4412-4420.
16. Deng W, Wang H, Rosenberg PA, Volpe JJ, Jensen FE. Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. Proc Natl Acad Sci U S A 2004;101: 7751-7756.
17. Manning SM, Talos DM, Zhou C, et al. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J Neurosci 2008;28:6670-6678.
18. Newcombe J, Uddin A, Dove R, et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 2008;18: 52-61.
19. Brand-Schieber E, Werner P. (+/-)-Alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid and kainate receptor subunit expression in mouse versus rat spinal cord white matter: similarities in astrocytes but differences in oligodendrocytes. Neurosci Lett 2003;345:126-130.
20. Brand-Schieber E, Werner P. AMPA/kainate receptors in mouse spinal cord cell-specific display of receptor subunits by oligodendrocytes and astrocytes and at the nodes of Ranvier. Glia 2003;42:12-24.
21. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
22. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67-70.
23. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6: 62-66.
24. Wallstrom E, Diener P, Ljungdahl A, Khademi M, Nilsson CG, Olsson T. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 1996;137:89-96.
25. Barger SW, Basile AS. Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. J Neurochem 2001;76:846-854.
26. Piani D, Fontana A. Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol 1994;152:3578-3585.
27. Li S, Mealing GA, Morley P, Stys PK. Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+-dependent glutamate transport. J Neurosci 1999;19:RC16.
28. Hamilton N, Vayro S, Wigley R, Butt AM. Axons and astrocytes release ATP and glutamate to evoke calcium signals in NG2-glia. Glia 2009 Jun 16. [Epub ahead of print].
29. Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007;85:2059-2070.